GLP-1s, visceral fat and inflammation
Visceral fat, liver fat, body weight and inflammation markers are different outcomes. A study showing a change in one does not automatically establish the same change in the others. The first step is to identify exactly what the researchers measured.
Visceral fat refers to fat around internal organs; a scale measures total body weight. Blood markers provide another kind of information. This guide explains those distinctions and the studies behind common GLP-1 claims, without treating a catalogue vial as the medicine or formulation used in a trial.
Are visceral fat, liver fat and body weight the same outcome?
Visceral adipose tissue is fat within the abdominal cavity around organs. Subcutaneous abdominal fat lies under the skin. Liver fat is a separate tissue measurement, and body weight includes much more than fat. A smaller waist or lower body weight can be relevant to a study without proving a specific change in any one compartment.
When reading a paper, record whether the endpoint was measured by imaging, estimated from another variable or not measured at all. An MRI substudy supports a different claim from a trial reporting weight alone. This distinction also prevents the common mistake of reading an abdominal-fat result as selective fat loss with no change in other tissues.
What did semaglutide studies find about inflammation markers?
An analysis of the STEP 1, 2 and 3 trials examined C-reactive protein (CRP), a blood biomarker of inflammation. Semaglutide groups had lower CRP than placebo at 68 weeks. Reductions occurred alongside weight loss and correlated with changes in body weight and other metabolic measurements.
That supports a measured biomarker effect in the studied populations. It does not establish that the entire change came from a direct effect on immune cells, or that all inflammatory conditions would respond similarly. CRP is an informative endpoint, but it is not a complete description of immune function.
For a mechanistic question, look for experiments that distinguish receptor signaling from changes in food intake, body composition and glucose regulation. If those influences are not separated by the design, retain them as possible explanations.
What can tirzepatide imaging studies show?
SURPASS-3 MRI compared tirzepatide with insulin degludec in a subgroup of adults with type 2 diabetes. The investigators measured liver fat and abdominal adipose tissue by MRI and reported reductions in liver fat, visceral adipose tissue and abdominal subcutaneous adipose tissue with tirzepatide relative to the comparator.
The population and comparator are part of the finding. This was not a trial of otherwise healthy research-vial customers, and it was not a direct comparison against retatrutide. The reduction in multiple fat compartments also does not support describing the result as exclusive targeting of visceral fat.
Does a proposed mechanism explain the whole result?
| Reported result | What still needs evidence |
|---|---|
| Lower CRP | Which pathways caused the change and whether clinical outcomes improved |
| Less visceral fat on MRI | Whether the effect is independent of overall weight change |
| A receptor response in cells | Whether the same exposure and response occur in people |
| Greater weight reduction | The contribution of fat, lean tissue, intake and energy expenditure |
Use this distinction when choosing an assay: a receptor readout should answer a receptor question, while a tissue-level outcome needs a model that measures tissue behavior. Statistical association alone cannot fill in the unmeasured steps between the two.
Why does tesamorelin need a separate comparison?
Tesamorelin is a growth hormone-releasing hormone analog, not a GLP-1 agonist. A randomized study in people with HIV and abdominal fat accumulation assessed visceral and liver fat. Its findings belong to that specific population and mechanism, not a general ranking of weight-loss compounds.
Can an improved marker prove a specific symptom will improve?
Not by itself. A marker can be useful without being a direct measure of symptoms or long-term health outcomes. Check whether the study measured the outcome being claimed and whether its participants match the population under discussion.
EPS documentation
Use the research catalogue to check the exact name, labelled amount and format. The COA library publishes the original Janoshik reports selected for EPS, retaining the original report client name and any missing batch fields. Literature findings and another supplier's analytical results are not evidence about an EPS batch.